Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

Objective: To assess the cost-effectiveness of dabigatran etexilate ('dabigatran') vs vitamin K
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …

Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …

Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …

Aims The aim of this study was to compare the clinical effectiveness and safety of direct oral
anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice …

Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral
anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review …

Methods From 1 January to 31 December 2012, 98,213 AF patients were selected from the
NHIRD database. A Markov model was constructed that combined published secondary …